Latest News

28 August 2017

Starpharma annual report and full year financial results

Melbourne, Australia; 28 August 2017: Starpharma (ASX: SPL, OTCQX: SPHRY) today released its annual report and financial results for the year ended 30 June 2017.


 

Read more

24 August 2017

Starpharma to present at Finance News Network Investor Event

Starpharma is presenting at the Finance News Network (FNN) Investor event in Sydney.

Read more

9 August 2017

Starpharma and Monash awarded STEM+ Business Fellowships

Starpharma today announced that Starpharma and Monash Institute of Pharmaceutical Sciences (MIPS) have been awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows. 

Read more

7 August 2017

Successful VivaGel® Phase 3 results and NDA planned for rBV

Starpharma today announced that its two phase 3 trials of VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) achieved their primary objective demonstrating statistically significant superiority compared to placebo in preventing rBV based on topline data.

Read more

In the media

28 August 2017

Starpharma featured on Sky Business News

Starpharma CEO Dr Jackie Fairly was interviewed on Sky Business News’ Ticky following the company’s successful Phase 3 trial results for VivaGel® BV for the treatment of recurrent bacterial vaginosis. Dr Fairley discussed the commercial significance of the announcement and liaising with the US FDA to bring the product to market.

To watch the interview, click here

24 August 2017

Starpharma CEO on Finance News Network

Finance News Network featured Dr Jackie Fairley as she discussed the company’s VivaGel® BV Phase 3 results for recurrent bacterial vaginosis, the company's sale of its agrochemical business for $35M, and progress with its DEP® drug delivery programs (both internal and external).

To watch the interview, click here

11 August 2017

Seeking Alpha covers Starpharma

Online stock market insights and research publication Seeking Alpha covered Starpharma’s Phase 3 results for VivaGel® BV for the treatment of recurrent bacterial vaginosis and noted the “substantial upside” of the announcement.

To view the article, click here.

10 August 2017

Starpharma and Monash awarded STEM+ Business fellowships

Biotech news and industry publication Biotech Dispatch covered the news that Starpharma and the Monash Institute of Pharmaceutical Sciences (MIPS) were awarded $300,000 in grant funding from the SIEF STEM+ Business Fellowship Program to engage two post-doctoral Research Fellows. The funding allows both Starpharma and Monash to further advance collaborative programs utilising Starpharma’s DEP platform.

To view the article, click here.

Shareholder Updates

4 July 2017

Shareholder Update July 2017

In this issue: 

>> Starpharma sells Agrochemicals business to Agrium for $35M cash

>> DEP®  irinotecan outperforms irinotecan in multiple cancer models

>> DEP®  docetaxel, DEP®  cabazitaxel and scale-up facilities

>> AstraZeneca pays US$2M DEP®  milestone to Starpharma

>> VivaGel®  BV phase 3 results timing and commercialisation

>> VivaGel®  condom launched in Canada

>> Sale of Ansell's Sexual Wellness division

>> Starpharma News & Events

Download: Shareholder Update July 2017 (pdf file, 710kb)

19 January 2017

Shareholder Update January 2017

In this issue:

›› Enrolment completed for phase 3 program: VivaGel® BV for prevention of recurrence

›› VivaGel® BV granted QIDP and Fast Track designation by US FDA

›› Favourable revision to FDA guidance for BV Treatment

›› VivaGel® condom approved in Canada; licensed in China and Iran

›› New DEP® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies

›› DEP® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2

›› DEP® cabazitaxel shows no neutropenia

›› DEP® irinotecan internal program shows superior performance

Download: Shareholder January 2017 (pdf file, 751kb)


Sign up to receive news here

© Starpharma Holdings Limited 2017